tetano
Editor, Senior Moderator
Clin Exp Med
. 2023 Oct 31.
doi: 10.1007/s10238-023-01203-0. Online ahead of print. Impact of influenza immunity on the mortality among older adults hospitalized with COVID-19: a retrospective cohort study
Matthieu Coulongeat[SUP] 1 2 [/SUP], Julien Marlet[SUP] 3 4 [/SUP], Amal Aidoud[SUP] 5 6 [/SUP], Flora Donati[SUP] 7 8 [/SUP], Simon Jamard[SUP] 9 [/SUP], Sylvie Van Der Werf[SUP] 7 8 [/SUP], Camille Debacq[SUP] 5 [/SUP], Victoire Leroy[SUP] 5 10 11 [/SUP], Adrien Lemaignen[SUP] 9 [/SUP], Sandie Munier[SUP] 7 8 [/SUP], Bertrand Fougère[SUP] 5 11 [/SUP]
Affiliations
It has been suggested that the outcomes of coronavirus disease 2019 (COVID-19) are better in individuals having recently received an influenza vaccine than in non-vaccinated individuals. We hypothesized that this association depends on the humoral responses against influenza viruses. We aim to assess the relationship between the humoral immunity against influenza and the 3-month all-cause mortality among hospitalized older patients with COVID-19. We performed an exploratory retrospective study of older patients (aged 65 and over) hospitalized for confirmed COVID-19 between November 2020 and June 2021. Previous humoral responses to influenza viruses were assessed using a hemagglutination inhibition assay on routinely collected blood samples. The study's primary outcome was the 3-month all-cause mortality, and the secondary outcomes were severe COVID-19 (oxygen requirement ≥ 6 L/min or ventilatory support) and complications (kidney or heart failure, thrombosis and bacterial infection). In the cohort of 95 patients with COVID-19, immunity against influenza vaccine subtypes/lineages was not significantly associated with 3-month all-cause mortality, with an OR [95%CI] of 0.22 [0.02-1.95] (p = 0.174) for the H1N1pdm09 subtype, 0.21 [0.03-1.24] (p = 0.081) for A/Hong Kong/2671/2019 H3N2 subtype, 1.98 [0.51-8.24] (p = 0.329) for the B/Victoria lineage, and 1.82 [0.40-8.45] (p = 0.437) for the B/Yamagata lineage. Immunity against influenza vaccine subtypes/lineages was also not significantly associated with severity and complication. Immunity against influenza subtypes/lineages included in the 2020-2021 vaccine was not associated with a lower 3-month all-cause mortality among COVID-19 hospitalized patients.Trial registration: The study was approved by a hospital committee with competency for research not requiring approval by an institutional review board (Tours University Medical Center, Tours, France: reference: 2021_015). All patients give the informed consent.
Keywords: Aged; COVID-19; Influenza Human; Influenza vaccines; Mortality.
. 2023 Oct 31.
doi: 10.1007/s10238-023-01203-0. Online ahead of print. Impact of influenza immunity on the mortality among older adults hospitalized with COVID-19: a retrospective cohort study
Matthieu Coulongeat[SUP] 1 2 [/SUP], Julien Marlet[SUP] 3 4 [/SUP], Amal Aidoud[SUP] 5 6 [/SUP], Flora Donati[SUP] 7 8 [/SUP], Simon Jamard[SUP] 9 [/SUP], Sylvie Van Der Werf[SUP] 7 8 [/SUP], Camille Debacq[SUP] 5 [/SUP], Victoire Leroy[SUP] 5 10 11 [/SUP], Adrien Lemaignen[SUP] 9 [/SUP], Sandie Munier[SUP] 7 8 [/SUP], Bertrand Fougère[SUP] 5 11 [/SUP]
Affiliations
- PMID: 37906387
- DOI: 10.1007/s10238-023-01203-0
It has been suggested that the outcomes of coronavirus disease 2019 (COVID-19) are better in individuals having recently received an influenza vaccine than in non-vaccinated individuals. We hypothesized that this association depends on the humoral responses against influenza viruses. We aim to assess the relationship between the humoral immunity against influenza and the 3-month all-cause mortality among hospitalized older patients with COVID-19. We performed an exploratory retrospective study of older patients (aged 65 and over) hospitalized for confirmed COVID-19 between November 2020 and June 2021. Previous humoral responses to influenza viruses were assessed using a hemagglutination inhibition assay on routinely collected blood samples. The study's primary outcome was the 3-month all-cause mortality, and the secondary outcomes were severe COVID-19 (oxygen requirement ≥ 6 L/min or ventilatory support) and complications (kidney or heart failure, thrombosis and bacterial infection). In the cohort of 95 patients with COVID-19, immunity against influenza vaccine subtypes/lineages was not significantly associated with 3-month all-cause mortality, with an OR [95%CI] of 0.22 [0.02-1.95] (p = 0.174) for the H1N1pdm09 subtype, 0.21 [0.03-1.24] (p = 0.081) for A/Hong Kong/2671/2019 H3N2 subtype, 1.98 [0.51-8.24] (p = 0.329) for the B/Victoria lineage, and 1.82 [0.40-8.45] (p = 0.437) for the B/Yamagata lineage. Immunity against influenza vaccine subtypes/lineages was also not significantly associated with severity and complication. Immunity against influenza subtypes/lineages included in the 2020-2021 vaccine was not associated with a lower 3-month all-cause mortality among COVID-19 hospitalized patients.Trial registration: The study was approved by a hospital committee with competency for research not requiring approval by an institutional review board (Tours University Medical Center, Tours, France: reference: 2021_015). All patients give the informed consent.
Keywords: Aged; COVID-19; Influenza Human; Influenza vaccines; Mortality.